Department of Psychiatry, Treatment Research Program, Maryland Psychiatric Research Center, University of Maryland School of Medicine, 55 Wade Ave., Baltimore, MD 21228, USA.
J Psychiatr Res. 2012 Aug;46(8):987-93. doi: 10.1016/j.jpsychires.2012.04.019. Epub 2012 May 16.
The impact of co-morbid substance use on mortality is not well studied in psychotic disorders. The objective of this study was to examine the impact of substance use on mortality in people with psychotic disorders and alcohol and/or drug use. We examined the rate of substance use and the risk of substance use on mortality risk over a 4-10 year period in 762 people with psychotic disorders. Deceased patients were identified from the Social Security Death Index and the Maryland Division of Vital Records. Substance use was defined as regular and heavy use or abuse or dependence. Seventy seven percent had co-morbid lifetime substance use, with co-morbid cannabis and alcohol use occurring most commonly. Out of 762 subjects, 62 died during follow up. In a Cox model, predicted mortality risk was higher in age group 35-55 compared to <35 years and in males, but reduced in cannabis users. Overall five- (3.1% vs 7.5%) and ten-year mortality risk (5.5% vs. 13.6%) was lower in cannabis users than in non-users with psychotic disorders (p = 0.005) in a survival model. Alcohol use was not predictive of mortality. We observed a lower mortality risk in cannabis-using psychotic disorder patients compared to cannabis non-users despite subjects having similar symptoms and treatments. Future research is warranted to replicate these findings and to shed light on the anti-inflammatory properties of the endocannabinoid system and its role in decreased mortality in people with psychotic disorders.
合并物质使用对精神障碍患者死亡率的影响尚未得到充分研究。本研究旨在探讨物质使用对有精神障碍和酒精和/或药物使用的人群死亡率的影响。我们在 762 名精神障碍患者中检查了 4-10 年内物质使用的发生率以及物质使用对死亡率风险的影响。通过社会保障死亡指数和马里兰州生命记录部确定死亡患者。物质使用定义为常规和大量使用或滥用或依赖。77%的人有合并终生物质使用,合并大麻和酒精使用最常见。在 762 名受试者中,有 62 人在随访期间死亡。在 Cox 模型中,与 <35 岁相比,35-55 岁年龄组的预测死亡率风险更高,男性的预测死亡率风险也更高,但大麻使用者的预测死亡率风险降低。在生存模型中,与非使用者相比,有精神障碍的大麻使用者的五年(3.1%比 7.5%)和十年(5.5%比 13.6%)死亡率风险较低(p=0.005)。酒精使用与死亡率无相关性。尽管这些患者有相似的症状和治疗方法,但与非大麻使用者相比,使用大麻的精神障碍患者的死亡率风险较低。需要进一步的研究来复制这些发现,并阐明内源性大麻素系统的抗炎特性及其在精神障碍患者死亡率降低中的作用。